SHANGHAI — Abbisko co-founder Zhui Chen told a Shanghai conference audience that a clinical trial his company ran on a drug licensed to Merck KGaA finished in 11 months — a timeline so short that the German pharma's executives asked whether Abbisko would train their staff.

Chen's remark came on stage at the five-star Hilton in Shanghai's "Science City" district, where four biotech leaders pitched the speed, cost, and efficiency advantages of drug development in China over the United States — and, by implication, over Europe.

Abbisko, the Shanghai-based company Chen co-founded, now carries a $6 billion valuation.

The executives' tone was triumphant. On a balmy, overcast Sunday, they joked openly about how much faster and cheaper development runs in China than anywhere else in the world.

For R&D managers at Western pharmas, the claim invites scrutiny rather than acceptance. An 11-month trial completion for a licensed asset is a concrete, named data point, but the source material does not specify the trial's phase, enrollment size, indication, or endpoints — the variables that typically determine whether a timeline is genuinely comparable across regions. Merck KGaA's request for staff training, if it happened as described, signals that at least one major European licensor found the execution gap credible enough to investigate.

The $6 billion valuation attached to Abbisko provides a second anchor. It reflects investor appetite for China-based developers whose cost and speed claims are increasingly backed by licensed assets flowing to Western partners — deals that transfer both molecules and, in this case, apparently operational know-how in the other direction.

What the executives did not supply, at least in the reported remarks, is a breakdown of where the efficiency gains come from: patient recruitment velocity, lower site costs, regulatory pathway differences, or internal process choices. Each of those has different implications for whether the model is exportable or dependent on structural conditions — labor costs, hospital networks, trial population density — that U.S. and European operators cannot simply replicate.

The setting itself carries weight. Shanghai's Science City district, with its glass towers and conference infrastructure, is the physical expression of a state-backed push to make the city a default venue for global biotech dealmaking. Executives making their pitch there are selling not only individual companies but China's ecosystem as a licensing and development partner of first resort.

For portfolio decision-makers, the operative questions are straightforward. If Chinese developers can reliably compress trial timelines toward the 11-month mark that Abbisko reported, the effective cost per clinical data point drops, and the relative value of in-house Western development pipelines shifts. If the advantage proves narrower or trial-specific, the licensing logic weakens.

The full account of the executives' presentations — including the additional claims from the other three biotech leaders on stage — is available to STAT+ subscribers.